The enhanced biological functions of B cells controlled by CXCL12 and its receptor CXCR4 prompted us to evaluate whether the adoptive transfer of CXCR4+ B cells is an optional and feasible immunotherapy for HCC. The gene discussed is CXCL12; the disease is hepatocellular carcinoma.